These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 18386000)

  • 81. Escherichia coli-based production of a tumor idiotype antibody fragment--tetanus toxin fragment C fusion protein vaccine for B cell lymphoma.
    Patel KG; Ng PP; Levy S; Levy R; Swartz JR
    Protein Expr Purif; 2011 Jan; 75(1):15-20. PubMed ID: 20851769
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated.
    Harrop R; Ryan MG; Myers KA; Redchenko I; Kingsman SM; Carroll MW
    Cancer Immunol Immunother; 2006 Sep; 55(9):1081-90. PubMed ID: 16311730
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments.
    Cheng WF; Hung CF; Hsu KF; Chai CY; He L; Ling M; Slater LA; Roden RB; Wu TC
    Hum Gene Ther; 2001 Feb; 12(3):235-52. PubMed ID: 11177561
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.
    Saif JM; Vadakekolathu J; Rane SS; McDonald D; Ahmad M; Mathieu M; Pockley AG; Durrant L; Metheringham R; Rees RC; McArdle SE
    Eur J Immunol; 2014 Apr; 44(4):994-1004. PubMed ID: 24338683
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53.
    Soong RS; Trieu J; Lee SY; He L; Tsai YC; Wu TC; Hung CF
    PLoS One; 2013; 8(2):e56912. PubMed ID: 23457640
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice.
    Zhao X; Bose A; Komita H; Taylor JL; Chi N; Lowe DB; Okada H; Cao Y; Mukhopadhyay D; Cohen PA; Storkus WJ
    J Immunol; 2012 Feb; 188(4):1782-8. PubMed ID: 22246626
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
    Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.
    Yu X; Guo C; Yi H; Qian J; Fisher PB; Subjeck JR; Wang XY
    Cancer Res; 2013 Apr; 73(7):2093-103. PubMed ID: 23333935
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine.
    Wu Y; Wan T; Zhou X; Wang B; Yang F; Li N; Chen G; Dai S; Liu S; Zhang M; Cao X
    Cancer Res; 2005 Jun; 65(11):4947-54. PubMed ID: 15930317
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L).
    Lorenz MG; Kantor JA; Schlom J; Hodge JW
    Hum Gene Ther; 1999 May; 10(7):1095-103. PubMed ID: 10340542
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity.
    Whittington PJ; Radkevich-Brown O; Jacob JB; Jones RF; Weise AM; Wei WZ
    Cancer Immunol Immunother; 2009 May; 58(5):759-67. PubMed ID: 18836716
    [TBL] [Abstract][Full Text] [Related]  

  • 94. DNA fusion vaccines against B-cell tumors.
    Zhu D; Rice J; Savelyeva N; Stevenson FK
    Trends Mol Med; 2001 Dec; 7(12):566-72. PubMed ID: 11733220
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.
    Osada T; Berglund P; Morse MA; Hubby B; Lewis W; Niedzwiecki D; Yang XY; Hobeika A; Burnett B; Devi GR; Clay TM; Smith J; Kim Lyerly H
    Cancer Immunol Immunother; 2012 Nov; 61(11):1941-51. PubMed ID: 22488274
    [TBL] [Abstract][Full Text] [Related]  

  • 96. CEA Plasmid as Therapeutic DNA Vaccination against Colorectal Cancer.
    Veisi Malekshahi Z; Hashemi Goradel N; Shakouri Khomartash M; Maleksabet A; Kadkhodazadeh M; Kardar GA; Negahdari B
    Iran J Immunol; 2019 Sep; 16(3):235-245. PubMed ID: 31552832
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Self-Replicating RNAs Drive Protective Anti-tumor T Cell Responses to Neoantigen Vaccine Targets in a Combinatorial Approach.
    Maine CJ; Richard G; Spasova DS; Miyake-Stoner SJ; Sparks J; Moise L; Sullivan RP; Garijo O; Choz M; Crouse JM; Aguilar A; Olesiuk MD; Lyons K; Salvador K; Blomgren M; DeHart JL; Kamrud KI; Berdugo G; De Groot AS; Wang NS; Aliahmad P
    Mol Ther; 2021 Mar; 29(3):1186-1198. PubMed ID: 33278563
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells.
    Xia J; Tanaka Y; Koido S; Liu C; Mukherjee P; Gendler SJ; Gong J
    J Immunol; 2003 Feb; 170(4):1980-6. PubMed ID: 12574367
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine.
    Maruyama H; Zaloudik J; Li W; Sperlagh M; Koido T; Somasundaram R; Scheck S; Prewett M; Herlyn D
    Cancer Immunol Immunother; 2000 Jun; 49(3):123-32. PubMed ID: 10881691
    [TBL] [Abstract][Full Text] [Related]  

  • 100. CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy.
    Frangione V; Mortara L; Castellani P; De Lerma Barbaro A; Accolla RS
    Int J Cancer; 2010 Oct; 127(7):1614-24. PubMed ID: 20091859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.